We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Amgen Sues Pfizer, Hospira in Neulasta Patent Dispute
Amgen Sues Pfizer, Hospira in Neulasta Patent Dispute
Amgen is calling for a jury trial for Hospira in the U.S. District Court for the District of Delaware, alleging that the Pfizer subsidiary’s proposed Neulasta (pegfilgrastim) biosimilar infringed on its patents for the anti-infection drug.